174 related articles for article (PubMed ID: 16186469)
1. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials.
Shefet D; Robenshtok E; Paul M; Leibovici L
Arch Intern Med; 2005 Sep; 165(17):1992-2000. PubMed ID: 16186469
[TBL] [Abstract][Full Text] [Related]
2. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.
Robenshtok E; Shefet D; Gafter-Gvili A; Paul M; Vidal L; Leibovici L
Cochrane Database Syst Rev; 2008 Jan; (1):CD004418. PubMed ID: 18254049
[TBL] [Abstract][Full Text] [Related]
3. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.
Shefet D; Robenshtock E; Paul M; Leibovici L
Cochrane Database Syst Rev; 2005 Apr; (2):CD004418. PubMed ID: 15846713
[TBL] [Abstract][Full Text] [Related]
4. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.
Eliakim-Raz N; Robenshtok E; Shefet D; Gafter-Gvili A; Vidal L; Paul M; Leibovici L
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD004418. PubMed ID: 22972070
[TBL] [Abstract][Full Text] [Related]
5. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
Mills GD; Oehley MR; Arrol B
BMJ; 2005 Feb; 330(7489):456. PubMed ID: 15684024
[TBL] [Abstract][Full Text] [Related]
7. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
Piso RJ; Arnold C; Bassetti S
Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
[TBL] [Abstract][Full Text] [Related]
8. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials.
Skalsky K; Yahav D; Lador A; Eliakim-Raz N; Leibovici L; Paul M
Clin Microbiol Infect; 2013 Apr; 19(4):370-8. PubMed ID: 22489673
[TBL] [Abstract][Full Text] [Related]
9. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
11. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
12. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
13. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.
Sligl WI; Asadi L; Eurich DT; Tjosvold L; Marrie TJ; Majumdar SR
Crit Care Med; 2014 Feb; 42(2):420-32. PubMed ID: 24158175
[TBL] [Abstract][Full Text] [Related]
14. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM
J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448
[TBL] [Abstract][Full Text] [Related]
15. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
Lee JS; Giesler DL; Gellad WF; Fine MJ
JAMA; 2016 Feb; 315(6):593-602. PubMed ID: 26864413
[TBL] [Abstract][Full Text] [Related]
17. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
Yuan X; Liang BB; Wang R; Liu YN; Sun CG; Cai Y; Yu XH; Bai N; Zhao TM; Cui JC; Chen LA
J Chemother; 2012 Oct; 24(5):257-67. PubMed ID: 23182045
[TBL] [Abstract][Full Text] [Related]
18. Are new antibiotics better than beta-lactams for non-critical inpatients with community-acquired pneumonia?
Reyes B T; Ortega G M; Saldías P F
Medwave; 2016 Aug; 16 Suppl 3():e6499. PubMed ID: 27512983
[TBL] [Abstract][Full Text] [Related]
19. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.
Li JZ; Winston LG; Moore DH; Bent S
Am J Med; 2007 Sep; 120(9):783-90. PubMed ID: 17765048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
